Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?
作者信息
Abdallah Nadine, Kim Seongho, Ayash Lois, Klimecki Scott, Ventimiglia Marie, Alavi Asif, Ratanatharathorn Voravit, Uberti Joseph, Deol Abhinav
机构信息
Department of Medicine, Wayne State University/Detroit Medical Center, Detroit, MI, USA.
Department of Oncology, Wayne State University/Karmanos Cancer Institute, Detroit, MI, USA.
出版信息
Bone Marrow Transplant. 2020 Aug;55(8):1655-1657. doi: 10.1038/s41409-019-0744-5. Epub 2019 Nov 18.
Abstract
摘要
相似文献
1
Does use of biosimilar G-CSF change plerixafor utilization during stem cell mobilization for autologous stem cell transplant?在自体干细胞移植的干细胞动员过程中，使用生物类似物粒细胞集落刺激因子（G-CSF）是否会改变普乐沙福的使用情况？
Bone Marrow Transplant. 2020 Aug;55(8):1655-1657. doi: 10.1038/s41409-019-0744-5. Epub 2019 Nov 18.
2
The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by "on-demand" addition of plerixafor to granulocyte-colony-stimulating factor.按需添加培哚普利福（plerixafor）对粒细胞集落刺激因子动员的 CD34+造血细胞的 CXCR4 和黏附分子表达。
Transfusion. 2014 Sep;54(9):2325-35. doi: 10.1111/trf.12632. Epub 2014 Mar 28.
3
[A Single-Center Analysis of the Use of G-CSF Combined with Plerixafor to Mobilize Peripheral Blood Hematopoietic Stem Cell from Healthy Related Donors in Allogeneic Hematopoietic Stem Cell Transplantation].[一项关于在异基因造血干细胞移植中使用粒细胞集落刺激因子（G-CSF）联合普乐沙福动员健康相关供者外周血造血干细胞的单中心分析]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Feb;30(1):286-291. doi: 10.19746/j.cnki.issn.1009-2137.2022.01.047.
4
Use of plerixafor to mobilize haematopoietic progenitor cells in healthy donors.培瑞克昔福在健康供者中动员造血祖细胞的应用。
Vox Sang. 2022 Jan;117(1):6-16. doi: 10.1111/vox.13175. Epub 2021 Jun 23.
5
EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors.EMA 关于培洛昔康（莫佐比拉）儿科适应证的建议，以增强淋巴瘤或恶性实体瘤儿童造血干细胞的动员，用于采集和随后的自体移植。
Oncologist. 2020 Jun;25(6):e976-e981. doi: 10.1634/theoncologist.2019-0898. Epub 2020 Mar 10.
6
Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.plerixafor 用于自体造血细胞移植动员的策略：疗效和成本比较。
Transfus Apher Sci. 2022 Apr;61(2):103303. doi: 10.1016/j.transci.2021.103303. Epub 2021 Oct 30.
7
Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixafor.使用普乐沙福在镰状细胞病患者中进行安全有效的外周血干细胞采集。
Haematologica. 2020 Oct 1;105(10):e497. doi: 10.3324/haematol.2019.236182.
8
Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption.生物类似物 G-CSF（格拉司琼）在自体外周血造血干细胞动员中的真实世界临床经验：加拿大早期采用后的单中心经验。
Curr Oncol. 2021 Apr 22;28(3):1571-1580. doi: 10.3390/curroncol28030148.
9
The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.在多发性骨髓瘤患者自体干细胞移植中，在粒细胞集落刺激因子（G-Csf）和化疗基础上加用普乐沙福的时机，会影响免疫恢复。
Bone Marrow Transplant. 2020 May;55(5):946-954. doi: 10.1038/s41409-019-0756-1. Epub 2019 Nov 25.
10
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.普乐沙福用于既往接受氟达拉滨或来那度胺治疗的患者的自体外周血造血干细胞动员。
Biol Blood Marrow Transplant. 2012 Feb;18(2):314-7. doi: 10.1016/j.bbmt.2011.10.003. Epub 2011 Oct 13.
本文引用的文献
1
2
Zarxio (Filgrastim-sndz): First Biosimilar Approved in the United States.择捷美（重组人粒细胞刺激因子-sndz）：首个在美国获批的生物类似药。
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):150-4.
Zotero 插件